Skip to content
MarketScale
‹ Back to IndustriesHealthcare

White House Turns to Big Tech to Fight Coronavirus: Business Casual

On this episode of MarketScale’s Business Casual, hosts Tyler Kern and Voice of B2B Daniel Litwin discuss U.S. Chief Technology Officer Michael Kratsios’ remote conference call to some of the biggest players in tech, requesting their help in mapping out a response plan to the COVID-19 pandemic. So, what exactly is the White House…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
White House Turns to Big Tech to Fight Coronavirus: Business Casual

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

On this episode of MarketScale’s Business Casual, hosts Tyler Kern and Voice of B2B Daniel Litwin discuss U.S. Chief Technology Officer Michael Kratsios’ remote conference call to some of the biggest players in tech, requesting their help in mapping out a response plan to the COVID-19 pandemic.

So, what exactly is the White House asking of these Big Tech companies, including Google, Facebook, Amazon, Microsoft, Apple, IBM, Cisco and Twitter?

According to Litwin and Kern, a variety of things, including helping to coordinate against misinformation around the virus, helping aid in medical research analysis, and also helping support the broader digital infrastructure that can enable the U.S. to track travelers as they fly, ensuring that we aren’t inadvertently increasing the spread of the coronavirus in our country.

With Big Tech often thought of as being the “bad guy”, the Trump administration’s request makes for an interesting dynamic, more or less placing these companies in the saddle of the white horse that will come in to slay the coronavirus dragon, thereby saving the day.

But this shift in dynamic raises many privacy concerns, especially when you consider we’ve seen a similar dynamic emerge in the wake of tragedy: the Patriot Act passed in response to the 9/11 tragedy. Highly-criticized and considered excessive and possibly unconstitutional by many, the Act expanded the government’s ability to gather surveillance as well as the collection and storage of U.S. citizens’ phone and internet metadata—data that communications companies were then required to hand over.

With Twitter already stating they may start flagging tweets that are “fake news,” Litwin asked, “Who ends up being the determinant of ‘is this fake, is this not’? Who is the truthbearer up in the ivory tower? That kind of stuff is incredibly important to think about.” He further questioned, “And do we want to hand over the reins of what is appropriate and what isn’t appropriate in the public’s fear to Big Tech—companies that already face a lack of scrutiny in their privacy handlings and mishandlings?”

Listen to the podcast now as Litwin and Kern discuss and question other possible scenarios that may stem from the government’s request of Big Tech for their aid in curbing the spread of the coronavirus.

Coming to you on Wednesdays and Fridays each week, tune into Business Casual to stay on top of the most recent trends and hottest topics impacting B2B.

For the latest news, videos, and podcasts in the Software & Technology Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512